FI962591A0 - Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä - Google Patents

Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä

Info

Publication number
FI962591A0
FI962591A0 FI962591A FI962591A FI962591A0 FI 962591 A0 FI962591 A0 FI 962591A0 FI 962591 A FI962591 A FI 962591A FI 962591 A FI962591 A FI 962591A FI 962591 A0 FI962591 A0 FI 962591A0
Authority
FI
Finland
Prior art keywords
growth hormone
pct
hormone releasing
compounds
date jun
Prior art date
Application number
FI962591A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962591L (fi
FI962591A7 (fi
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thoegersen
Birgit Sehested Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143893A external-priority patent/DK143893D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI962591L publication Critical patent/FI962591L/fi
Publication of FI962591A7 publication Critical patent/FI962591A7/fi
Publication of FI962591A0 publication Critical patent/FI962591A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI962591A 1993-12-23 1994-12-22 Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä FI962591A0 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK143893A DK143893D0 (cs) 1993-12-23 1993-12-23
DK7594 1994-01-17
DK78194 1994-06-30
DK116594 1994-10-07
PCT/DK1994/000486 WO1995017422A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (3)

Publication Number Publication Date
FI962591L FI962591L (fi) 1996-06-20
FI962591A7 FI962591A7 (fi) 1996-06-20
FI962591A0 true FI962591A0 (fi) 1996-06-20

Family

ID=27439242

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962591A FI962591A0 (fi) 1993-12-23 1994-12-22 Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä

Country Status (18)

Country Link
US (1) US5854211A (cs)
EP (1) EP0736038B1 (cs)
JP (1) JP3759748B2 (cs)
CN (1) CN1052730C (cs)
AT (1) ATE202785T1 (cs)
AU (1) AU683121B2 (cs)
CA (1) CA2179598A1 (cs)
CZ (1) CZ291382B6 (cs)
DE (1) DE69427650T2 (cs)
FI (1) FI962591A0 (cs)
HU (1) HU221092B1 (cs)
IL (1) IL112111A (cs)
NO (1) NO315611B1 (cs)
PL (1) PL181286B1 (cs)
RU (1) RU2167881C2 (cs)
TW (1) TW438810B (cs)
UA (1) UA45962C2 (cs)
WO (1) WO1995017422A1 (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
ES2268713T3 (es) 1995-12-13 2007-03-16 MERCK & CO., INC. Ensayos de receptores de secretagogos de la hormona de crecimiento.
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1999036431A1 (en) 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMIDE SECRETAGOGUES OF GROWTH HORMONE DERIVATIVES
US6551998B1 (en) * 1999-06-22 2003-04-22 University Of Louisville Research Foundation, Inc. Antimicrobial agents
EP1204321B1 (en) * 1999-07-26 2005-11-09 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
WO2001070672A2 (en) * 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
DE60133271T2 (de) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
WO2002072602A2 (en) * 2001-03-08 2002-09-19 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2373783T3 (es) 2003-09-12 2012-02-08 Tercica, Inc. Métodos para el tratamiento de la deficiencia de factor 1 de crecimiento similar a la insulina (igf-1).
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
MXPA06013754A (es) * 2004-05-25 2007-02-08 Pfizer Prod Inc Uso novedoso.
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
JPWO2016129645A1 (ja) 2015-02-10 2017-10-26 富士フイルム株式会社 光学部材、光学素子、液晶表示装置および近接眼光学部材
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US5480869A (en) * 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5470753A (en) * 1992-09-03 1995-11-28 Selectide Corporation Peptide sequencing using mass spectrometry
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
KR100354897B1 (ko) * 1993-12-23 2003-01-06 노보 노르디스크 에이/에스 성장호르몬방출성을갖는화합물

Also Published As

Publication number Publication date
US5854211A (en) 1998-12-29
TW438810B (en) 2001-06-07
CN1052730C (zh) 2000-05-24
AU1310695A (en) 1995-07-10
ATE202785T1 (de) 2001-07-15
JPH09506873A (ja) 1997-07-08
EP0736038B1 (en) 2001-07-04
IL112111A (en) 2000-07-16
FI962591L (fi) 1996-06-20
HU9601740D0 (en) 1996-08-28
HU221092B1 (en) 2002-08-28
FI962591A7 (fi) 1996-06-20
RU2167881C2 (ru) 2001-05-27
IL112111A0 (en) 1995-03-15
NO315611B1 (no) 2003-09-29
NO962664L (no) 1996-08-23
UA45962C2 (uk) 2002-05-15
NO962664D0 (no) 1996-06-21
CN1138334A (zh) 1996-12-18
CZ183396A3 (en) 1997-02-12
PL181286B1 (pl) 2001-07-31
DE69427650D1 (de) 2001-08-09
AU683121B2 (en) 1997-10-30
CZ291382B6 (cs) 2003-02-12
WO1995017422A1 (en) 1995-06-29
PL315114A1 (en) 1996-10-14
JP3759748B2 (ja) 2006-03-29
EP0736038A1 (en) 1996-10-09
CA2179598A1 (en) 1995-06-29
HUT74820A (en) 1997-02-28
DE69427650T2 (de) 2001-11-22

Similar Documents

Publication Publication Date Title
FI962591A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE188379T1 (de) Fibrinogenrezeptor-antagonisten
PT804252E (pt) Agentes queladores metalicos que contem monoaminas diamidas e tiois
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DK1077941T3 (da) Forbindelser med væksthormonfrigörende egenskaber
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
EE200100125A (et) TAN-1057 derivaadid
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ATE243521T1 (de) Verwendung von biopolymeren zur behandlung der muskeln
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
DE69503635D1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
TH32887A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
MA Patent expired